Established in 2011, the company focuses on the discovery, development, and commercialization of innovative biologics to address unmet medical needs. They aim to provide affordable and effective healthcare solutions to patients worldwide. Headquartered in Suzhou, China, xInnovent Biologics operates with a state-of-the-art research and development center, manufacturing facility, and corporate offices.

The headquarters also serve as the central hub for the company's global operations. The company's main products include biologic drugs in various therapeutic areas such as oncology, ophthalmology, autoimmune, and cardiovascular diseases. They have developed a diversified pipeline of biosimilars, bi-specific antibodies, and innovative immuno-oncology therapeutics.

Notably, xInnovent Biologics has successfully received approvals from regulatory authorities for several of their products, demonstrating their commitment to delivering high-quality treatments. On a global scale, xInnovent Biologics has established strategic partnerships and collaborations with renowned pharmaceutical companies. They have formed joint ventures with Eli Lilly and Company, Sanofi, and Incyte Corporation, among others, to accelerate the development and commercialization of their products worldwide.

These collaborations strengthen the company's R&D capabilities, broaden its global reach, and enhance its market presence. xInnovent Biologics has achieved significant success in terms of market positioning and global sales. They have rapidly expanded their business and solidified their position as one of the leading biopharmaceutical companies in China.

The company's quality products, strong partnerships, and commitment to innovation have earned them a competitive edge in the global biologics market. In terms of major events, xInnovent Biologics launched its initial public offering (IPO) on the Hong Kong Stock Exchange in October 2018. This IPO raised substantial funds, enhancing the company's financial capabilities and facilitating further growth and expansion.

As of the latest updates, xInnovent Biologics continues to advance its pipeline of products and expand its global presence. With ongoing research and development efforts, strategic partnerships, and a strong market position, the company is well-positioned for continued success and growth in the biopharmaceutical industry